drugset / Trial / NCT05194111
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan
RandomizedParallel-groupSingle-blindSupportive care
Summary
To determine feasibility of recruitment and tolerability of treatment with sacubitril-valsartan among adult age survivors of cancer diagnosed at or before age 39 who have stage B heart failure.
Timeline
- Start
- 2022-08-11
- Primary completion
- 2028-11-30
- Completion
- 2028-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carvedilol | Other / unclassified | 25 mg | Oral |
| Subject | Sacubitril-Valsartan | Unknown | — | Oral |
| Subject | Valsartan | Small molecule | 160 mg | Oral |